Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bayer Ag Ord (OP:BAYZF)

30.38 +0.38 (+1.27%)
Streaming Delayed Price Updated: 2:39 PM EST, Nov 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bayer Ag Ord

< Previous 1 2 3 Next >
ESG Stocks Take Center Stage As Damages From Climate-Related Events Rise Exponentially Within US
With climate change becoming a mega market force, ESG investing is rising. The XVV is up 28% YTD. Agri-Tech stocks like Bayer AG, FMC Corporation, and Corteva Inc are providing climate resilience... 
Via Benzinga
Topics Climate Change
Bayer Faces $3.5M Verdict in Fifth Consecutive Roundup Weedkiller Loss
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
Bayer Faces Growing Pressure Amid Roundup Lawsuits as Philadelphia Trial Nears Conclusion
The spotlight is on a Philadelphia trial as Bayer AG (OTC: BAYRY) (OTC: BAYZF) grapples with mounting legal challenges surrounding its Roundup weedkiller, prompted by multi-billion dollar verdicts  
Via Benzinga
Topics Lawsuit
German Conglomerate Bayer Faces Investor Scrutiny Amid Unexpected Legal, Trial Setbacks
Bayer AG (OTC: BAYRY) (OTC: BAYZF) reportedly held an investor call to address concerns after intense scrutiny from investors following a series of unforeseen setbacks, prompting questions about... 
Via Benzinga
Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence
Monday, Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Bayer's Kidney Disease Drug Disappoints On Cutting Cardiovascular Death
 
Via Benzinga
FDA Approves Expanded Use For Bayer's Prostate Cancer Drug
 
Via Benzinga
Bayer's Blood Thinner Study Stopped Early Due To Lack Of Efficacy: Details
Bayer AG (OTC: BAYRY) (OTC: BAYZF)  
Via Benzinga
Bayer's Legal Victory Against Merck: Delaware Court Rules In Company's Favor Regarding Talc Lawsuits
The Delaware Supreme Court reportedly ruled in favor of Bayer AG (OTC: BAYRY) (OTC: BAYZF), stating that the company is not accountable for lawsuits associated with talc-based foot powder products... 
Via Benzinga
Topics Lawsuit
Bayer CEO Resists Full Tri-Split, German Conglomerate Cuts Management Jobs In The Face Of Q3 Loss
Bayer AG (OTC: BAYRY) (OTC: BAYZF) CEO Bill Anderson announced  
Via Benzinga
Legal Woes Mount for Bayer As Roundup Weed Killer-Related Cancer Cases Continue, Faces Third Trial Loss
Bayer AG (OTC: BAYRY) (OTC:  
Via Benzinga
From Years to Months: How AI is Shaping the Landscape of Clinical Trials
Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These... 
Via Benzinga
Topics Artificial Intelligence
Hawaiian Electric Says Power Lines Not Responsible For Deadly Lahaina Fire, China Targets Stock Market Revival, FTC Pauses Legal Battle With Amgen's $28B Horizon Deal: Today's Top Stories
Reuters 
Via Benzinga
German Pharma Firm Bayer's New Parkinson's Treatment Shows Promise: What the Phase 1 Trial Reveals
Boston Scientific Corporation (NYSE: BSX) released 12-month results from the pivotal ADVENT trial of the FARAPULSE Pulsed Field Ablation (PFA) System, a nonthermal treatment in which electric fields... 
Via Benzinga
FDA Approves Regeneron Pharmaceuticals' Higher Dose Of Eylea For Age-Related Blindness
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) approved Eylea HD (aflibercept) Injection 8 mg for wet age-related macular degeneration (wAMD), diabetic macular edema (DME),  
Via Benzinga
AstraZeneca's Imfinzi/Imjudo Combo Shows Sustained Overall Survival Benefit At Four Years In Liver Cancer
AstraZeneca Plc (NASDAQ: AZN) released updated results from the HIMALAYA Phase 3 trial evaluating Imfinzi (durvalumab) plus Imjudo (tremelimumab-actl) in unresectable hepatocellular carcinoma (HCC)... 
Via Benzinga
Bayers Says Neuronal Stem Cell Therapy For Parkinson's Shows Encouraging Action In Early-Stage Study
Bayer AG (OTC: BAYRY) (OTC: BAYZF) and its subsidiary BlueRock Therapeutics LP announced  
Via Benzinga
US Court Favors Bayer In Lawsuit Against Merck On Talc Liabilities
 
Via Benzinga
Bayer Seeks To Double US Revenues Over Next Decade, With Planned R&D Spending Of Around $1B
Bayer AG (OTC: BAYRY) intends to shell out around $1 billion on drug research and development in the U.S. in 2023 as it works to double its sales in the U.S. over the next ten years. 
Via Benzinga
Bayer Bolsters Its Position In Digital Medical Imaging With Acquisition Of UK-Based Firm
 
Via Benzinga
FAA Technology Glitch Hits US Flights Operations, Coca-Cola & PepsiCo Under FTC Probe, Rivian Hit By Mass Executive Exodus: Today's Top Stories
Reuters 
Via Benzinga
Activist Investor Builds Stake In Bayer, Pushes Breakup
Activist investor Bluebell Capital Partners has built a stake in Bayer AG (OTC: BAYRY) (OTC: BAYZF) and is pushing it to split up.  
Via Benzinga
Ionis Regains Rights To Thrombosis Candidate From Bayer
 
Via Benzinga
Roundup Weedkiller Maker Bayer Won Five Consecutive Cases, Shifting Momentum In Bayer's Favor
Bayer AG (OTC: BAYRY) won five jury verdicts in a row in trials that contended its Roundup weed killer caused non-Hodgkin lymphoma. The company battles the remaining cases targeting its Roundup... 
Via Benzinga
After Investor Flak, German Healthcare Giant Bayer Starts Hunt For New CEO: Report
 
Via Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
 
Via Benzinga
Morning Brief: Top Financial Stories Dominating on Friday, June 10
Reuters Rebranded McDonald’s Restaurants To Reopen In Russia 
Via Benzinga
US Top Court To Decide On Bayer's Roundup Weedkiller Appeal
 
Via Benzinga
Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
 
Via Benzinga
FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs
The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.